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Acute and chronic cardiac toxicity is the most perplexing
reaction of doxorubicin. The acute syndrome is characterised
by rhythm disturbances, electrocardiographic abnormalities
and occasionally acute cardiac dilatation. The chronic
damage is dose-dependent and can lead to congestive heart
failure. 4'-epidoxorubicin (epirubicin) has been claimed to be
less cardiotoxic than doxorubicin, but the advantage is not
quantitatively impressive (Chabner & Myers, 1989).
Magnesium (Mg) is essential for activation of NA+/K+
ATPase pump, which plays a major role in regulating
NA+/K+ transport and in maintaining resting membrane
potentials (Altura BM and Altura BT, 1984). The direct and
indirect (through the effects on K+ and Ca"+ metabolism)
cardioprotective and antiarrhythmic properties of Mg are
well known (Dyckner & Wester, 1982; Iseri, 1984). Mg deficit
is associated with ventricular and supraventricular arrhy-
thmias, symptoms of cardiac failure and electrocardiographic
modifications, such low QRS voltages, extended Q-T interval
and ST-T tract abnormalities (Dyckner & Wester, 1979;
Dickner & Wester, 1982; Chen Wan Chun et al., 1982;
Rasmussen et al., 1986).
Mg is mainly an intracellular cation; intracellular deficit is
often not revealed by measurement of serum levels (Iseri,
1984; Ryzen et al., 1986; Abbasciano et al., 1988), and a
reliable evaluation of effective availability of Mg is achievable
only by an intracellular assay. In this study we evaluated the
changes in erythrocyte Mg concentrations (EMg) during
infusion of doxorubicin or epirubicin, administered alone or
in combination with other antineoplastic drugs, to verify
whether intracellullar Mg levels might have some relationship
with acute anthracycline-induced cardiotoxicity.
Twenty-six cancer patients (five males and 21 females, aged
46-63 years) gave their informed consent to the study.
Tumour types and chemotherapy regimens are reported in
Table I. No patient had hypertension, diabetes, coronary
artery disease or electrocardiographic abnormalities, and
none had received prior irradiation to the mediastinum.
EMg was measured just before (day 0) and 1, 2 and 7 days
after doxorubicin or epirubicin administration. Serum levels
of Mg, Na, K, Cl, Ca, CPK, LDH, ALT and AST were also
measured in all patients. Urinary Mg excretion (UMg) was
determined in 16 patients. EMg was assayed by atomic
absorption spectrophotometry on washed and purified red
blood cells, according to the method described elsewhere
(Locatelli et al., 1987); the other parameters were assayed
using standard laboratory methods.
During the period of observation all patients received the
same dietary regimen to avoid differences in Mg intake; no
diuretic was administered (with the exception of intravenous
furosemide 20 mg in two cases treated with the schedule
cisplatin + doxorubicin + cyclophosphamide). Vomiting was
controlled by intravenous metoclopramide or methylpred-
nisolone, which do not interfere with Mg homeostasis when
acutely administered (Quanne & Dirks, 1983). Each patient
had daily clinical and electrocardiographic evaluation, which
were done always by the same physician to ensure
homogeneity in evaluating cardiac changes; the increase of
20% or more in heart rate from pretreatment values was
considered as a 'minor' change; symptoms of cardiac
insufficiency, rhythm disturbances and electrocardiogram
(ECG) abnormalities were considered as 'major' changes.
The number of vomiting episodes and the possible onset of
diarrhoea was also registered for each patient. Clinical-
electrocardiographic evaluation and EMg assay were done
blind by two different physicians.
Essential results of the study are reported in Table I.
Serum levels of Mg, Na, K, Cl, Ca, LDH, CPK, AST and
ALT did not show significant changes. No symptoms of
cardiac failure were observed. Four patients had increase of
20% or more in heart rate and four had 'major' changes; all
cardiac disturbances were observed within 48 h from doxo-
rubicin or epirubicin administration. EMg increased within
48 h in 15 patients and decreased in 11. Only one patient
with increased EMg had 'minor' changes, whereas seven out
of 11 patients (63.6%) with reduced EMg had cardiac distur-
bances; three out of four 'major' changes were observed in
the patients who had the more marked reduction in EMg.
The difference is statistically significant either considering the
whole frequency of cardiac disturbances (P <0.01, using
Fisher's exact test) or considering the distribution in two
classes of severity (P <0.05, using chi-square test). The mean
percentage ± Standard Deviation of change in EMg from
pretreatment levels to the concentrations determined after
48 h was 10.98% 23.36 in the group without cardiac
modifications, and -21.85% ± 23.17 in the group with car-
diac disturbances. This difference is statistically significant
(P <0.01 using unpaired Wilcoxon's signed-rank test). In all
cases but one UMg decreased when EMg increased and vice
versa. The ECG of the patients with reduced QRS voltage
and ST-T tract abnormalities was still abnormal on the 7th
day; in these subjects EMg remained lower than pretreatment
levels. All other patients had recovered pretreatment EMg
levels and had normal ECG after 7 days.
No patient had diarrhoea; there was no difference in mean
number of vomiting episodes between the patients with
reduced and increased EMg. No difference in EMg and UMg
changes, in frequency and in severity of cardiac disturbances
was observed between doxorubicin and epirubicin, nor
between monochemotherapy and combination chemotherapies.
Direct measurement of myocardial Mg requires
endomyocardial biopsies; this technic cannot be employed in
serial studies on human subjects for obvious ethical reasons.
In clinical practice, the measurement of red cell Mg is the
basic method for evaluating cellular Mg metabolism (Dur-
lach, 1988). If the changes in EMg represent in some degree
similar changes in myocardial cells, our results suggest that
Mg might play some role in anthracycline-induced acute
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Table I Tumour types, chemotherapy regimens and essential results of the study
Tumour typea EMg/UMgc
and therapy' 0 1 2 7 %d Cardiac changes
l)Ov P+D+C 3.36 4.02 4.12 4.38 + 10.2 None
2) Br D 4.89/8 4.84/7 5.39/4 4.84/7 + 10.2 None
3) Br E+V 4.71/8 5.82/3.8 5.58/5.6 4.84/8 + 18.7 None
4) Br E+V 3.83/18 4.46/7.5 4.13/10 4.99/15 + 7.8 None
5) Br E+V 3.98 3.12 2.32 2.82 -41.7 ReducedQRSvoltage 6) Lu V+D+C 1.7/4.2 2.12/3 3.1/2.1 3.9/3.2 + 78.1 None
7) Br E 3.95/9 4.1/4 4.37/6 4.7/5.5 + 24 Increasedheart rate
8) Br D 4.35/1 3.63/3 3.4/3 4.24/8 -21.8 None
9) Ov P + D + C 5.24/8 3.34/6 3.4/4.4 3.8/6.2 - 35.1 ReducedQRSvoltage 10) Br E + V 2.82 2.92 3.88 3.38 + 37.5 None
l1)Occ D+V 4.15 4.33 4.69 4.53 + 13 None
12)0cc D+V 3.9/9.1 4.09/8 4.3/7.6 4.8/9.3 +9.6 None
13) Br D 4.84 3.26 1.82 3.87 - 62.4 Tachyfibrillation(170/min) 14) Lu V+D+C 3.06/7 3.4/6.1 2.73/8 3.04/9 - 10.8 Increased heart rate 15) Br D + V 3.7/4 3.2/6 3.5/7 3.7/3 - 5.4 Increased heart rate 16)Br E 2.84 2.91 3.34 3.28 + 17.6 None
17) Lu V+D+C 4.12/7.4 4.72/6 4.51/5.6 4.34/7 + 9.4 None
18) Br E 3.75 4.02 4.05 4.02 + 8 None 19)Occ E+V 2.26 2.38 2.63 2.51 + 16.3 None
20) Br D 4.48/8.4 4.27/8.4 3.83/11 4.3/10.8 - 14.5 None
21) Br E+V 5.38/5 5.02/6.7 4.6/7.5 4.47/10 - 16.9 ST-Tflatteningand inversion 22)0cc D+V 4.03/6 4.2/7 3.27/8.5 4.1/4.2 - 18.8 None
23) Br D + V 3.39 4.14 4.09 3.48 + 20.6 None
24) Br E + V 3.52 3.52 3.68 3.61 + 4.5 None 25)0cc E 4.21/7 3.94/9 3.32/9.9 4.28/8 -21.1 None
26) Br E+V 3.28/5.2 2.8/7.4 2.85/9 3.3/8.2 - 13.1 Increasedheartrate
aBr = Breast cancer; Lu = Lung cancer; Ov = Ovarian cancer; Occ = Occult neoplasia. bD = Doxorubicin 50mgmq' body surface area; E = Epirubicin 75 mgmq' b.s.a.; P = Cisplatin 50mgmq' b.s.a.; V = Vincristine 1.2mgmq-' b.s.a.; C=Cyclophosphamide 500mgmq-' b.s.a. in ovarian cancer and 750mgmq-' b.s.a. in lung cancer. cEMg=Erythrocyte Mg concentration (in Meq/l) UMg=Urinary Mg excretion (in Meq/24h) measured before (day 0) and 1, 2 and 7 days after chemotherapy administration. dPercentage of change in EMg from day 0 to day 2.
cardiotoxicity. Most of the existing evidence supports free- radicals formation as the basis for acute cardiotoxicity induced by anthracyclines; moreover doxorubicin reduces
glutathione peroxidase activity, a key enzyme in the detoxica- tion of peroxides (Myers et al., 1985; Chabner & Myers, 1989). Anthracyclines also have a direct action on cell mem-
brane, causing fluidity changes and alterating the organis- ation of membrane phospholipids (Myers et al., 1985). Mg has a stabilising effect for the cell membrane; its complexing with phospholipids reduces membrane fluidity and permeability (Durlach, 1988). Moreover Mg is pivotal in the synthesis of glutathione and in the transfer, storage and utilisation of energy, regulates redox reactions and maintains the coupling of oxidation and phosphorylation in mitochon- dria (Iseri, 1984; Durlach, 1988). All these functions could be useful in protecting myocardial cells against anthracycline- induced injury, and it is possible that the cell requirement of Mg increases during the administration of doxorubicin and epirubicin, to counterbalance the toxic effects of the drugs. In some predisposed patients the cells might be unable to in- crease their Mg content, owing to enhanced susceptibility to the direct action of anthracyclines on cell membrane, with formation of covalent bindings to membrane structures
(Myers et al., 1985) and consequent leakage of membrane Mg and/or inability of the cells to uptake serum Mg. The
risk of acute cardiotoxicity would be higher in such patients:
indeed we obserged 'major' ECG changes only in patients
with reduced EMg.
Prolonged infusion ofdoxorubicin seems to reduce chronic
cardiotoxicity (Speyer et al., 1985). This observation supports
the hypothesis that cardiotoxicity is related to repeated high
concentrations of the drug, which would induce an acute
myocarditis-like effect (Shapira et al., 1990), rather than to
the total cumulative dose (Alexander et al., 1979): the sum of
repeated acute toxic effects would lead to the chronic damage
(Piver et al., 1985). Our preliminary data suggest a relation-
ship between intracellular Mg concentrations and anthra-
cycline-induced acute toxic effects on the heart: might the
monitoring of intracellular Mg levels have some value in
predicting the development of the chronic damage? More
work is necessary to test this idea.
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